[시장보고서]세계의 프리필드 시린지 시장 : 유형별, 디자인별, 소재별, 용도별, 지역별

세계의 프리필드 시린지 시장 : 유형별, 디자인별, 소재별, 용도별, 지역별 - 예측(-2030년)

Prefilled Syringes Market by Type (Conventional, Safety), Material (Glass Prefilled Syringe, Plastic), Design (Single-Chamber Prefilled Syringe, Dual-Chamber), Application (Diabetes, Cancer, and Rheumatoid Arthritis), & Region - Global Forecast to 2030

상품코드 : 1526808 해당 상품은 즉시 배송 가능합니다

리서치사 : MarketsandMarkets

발행일 : 2024년 07월

페이지 정보 : 영문 293 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,109,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650

￦ 9,550,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150

￦ 11,705,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,362,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

프리필드 시린지 시장 규모는 예측 기간 동안 10.8%의 CAGR로 확대되어 2024년 71억 달러에서 2030년 131억 달러에 달할 것으로 예상됩니다.

프리필드 시린지 시장은 당뇨병, 류마티스 관절염, 심혈관 질환과 같은 만성 질환의 유병률 증가 등 여러 요인으로 인해 높은 성장세를 보이고 있습니다. 또한, 프리필드 시린지는 즉시 사용 가능한 용량을 제공함으로써 환자의 순응도를 높이고 투약 오류 가능성을 낮춰 만성질환 환자에게 정확하고 일관된 약물 투여를 용이하게 합니다. 또한, 자가 투약의 증가 추세도 시장 성장에 큰 역할을 하고 있습니다. 프리필드 시린지는 용량 측정이 필요 없어 안전성이 향상되고, 오염 위험이 낮으며, 편안함과 사용 편의성으로 인해 환자들에게 선호되고 있습니다.

조사 범위
조사 대상 연도	2022-2030년
기준 연도	2023년
예측 기간	2024-2030년
검토 단위	금액(10억 달러)
부문별	유형별, 디자인별, 소재별, 용도별, 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카, GCC 국가

유형별로는 몇 가지 요인으로 인해 기존 프리필드 시린지 부문이 프리필드 시린지 시장을 주도할 것으로 예상됩니다. 프리필드 시린지는 즉시 사용 가능한 특성과 미리 계량된 용량으로 인해 준비 시간과 투약 오류를 줄이고 편의성과 안전성을 높입니다. 사전 충전된 주사기는 첨단 안전 기능을 통해 오염 위험과 바늘에 찔리는 손상을 줄일 수 있습니다. 사용 편의성이 뛰어나 치료 요법 순응도를 높이고, 특히 만성 질환 환자의 순응도를 향상시킵니다. 치료 용도, 특히 생물학적 제제 및 만성 질환 치료에서 다재다능함은 이러한 질환의 유병률 증가와 함께 시장에서의 우위를 더욱 강화합니다.

재료별로는 유리 프리필드 시린지 부문이 프리필드 시린지 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 유리 주사기는 우수한 화학적 불활성 특성으로 약물의 안정성을 보장하고 약물과 용기의 상호 작용 위험을 감소시켜 다양한 제약 응용 분야에 이상적입니다. 또한, 유리 주사기는 가시성이 뛰어나 약물의 미립자나 변색을 쉽게 검사할 수 있어 품질 관리와 환자 안전에 매우 중요합니다. 그 결과, 제약회사와 의료 서비스 제공자는 약물전달의 신뢰성, 안전성 및 효율성 때문에 유리 프리필드 시린지를 선호하고 있습니다.

디자인별로 보면 단일 챔버 프리필드 주사기 부문은 약물 투여의 편의성, 안전성 및 효율성 때문에 프리필드 주사기 시장에서 가장 큰 시장 점유율을 차지하고 있습니다. 환자의 안전성을 높입니다. 또한, 주사 과정을 간소화하여 의료진과 환자가 빠르고 쉽게 주사할 수 있어 순응도 및 치료 결과를 개선할 수 있습니다. 그러나 다양한 치료 분야, 특히 만성 질환 관리 및 응급 의료 분야에서 널리 채택되고 있다는 점이 시장 성장을 더욱 촉진하고 있습니다.

이 보고서는 전 세계 프리필드 시린지 시장을 조사하여 유형별, 디자인별, 소재별, 용도별, 지역별 동향, 시장 진입 기업 개요 등을 정리했습니다.

소개
시장 역학
업계 동향
기술 분석
밸류체인 분석
Porter's Five Forces 분석
규제 상황
사례 연구 분석
가격 분석
미충족 수요
생태계 분석
공급망 분석
인접 시장 분석
고객의 비즈니스에 영향을 미치는 동향/혼란
무역 분석
특허 분석
2024-2025년의 주요 회의와 이벤트
주요 이해관계자와 구입 기준
투자와 자금 조달 시나리오
상환 시나리오
프리필드 시린지 부품 시장 분석

제6장 프리필드 시린지 시장(유형별)

소개
기존 프리필드 시린지
세이프티 프리필드 시린지

제7장 프리필드 시린지 시장(디자인별)

소개
싱글 챔버 프리필드 시린지
듀얼 챔버 프리필드 시린지
맞춤형 프리필드 시린지

제8장 프리필드 시린지 시장(소재별)

소개
유리 프리필드 시린지
플라스틱 프리필드 시린지

제9장 프리필드 시린지 시장(용도별)

소개
당뇨병
류마티스 관절염
아나필락시스
암
혈전증
안과
기타

제10장 프리필드 시린지 시장(지역별)

소개
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
GCC 국가

제11장 경쟁 상황

개요
주요 진출 기업 전략/비책
매출 분석
시장 점유율 분석
기업 평가 매트릭스 : 주요 진출 기업, 2023년
기업 평가 매트릭스 : 스타트업/중소기업, 2023년
브랜드/제품 비교
연구개발비
경쟁 상황
기업 평가와 재무 지표

제12장 기업 개요

주요 진출 기업
- BD
- GERRESHEIMER AG
- SCHOTT
- WEST PHARMACEUTICAL SERVICES, INC.
- APTARGROUP, INC.
- NIPRO
- BAXTER(SIMTRA)
- OWEN MUMFORD LTD.
- WEIGAO MEDICAL INTERNATIONAL CO., LTD
- CREDENCE MEDSYSTEMS, INC.
- NOVARTIS AG
- STEVANATO GROUP
- POLYMEDICURE
- MEDXL INC.
- SHARPS TECHNOLOGY, INC.
기타 기업
- FRESENIUS KABI USA
- MEDEFIL, INC.
- D.B.M. S.R.L.
- TAISEI KAKO CO., LTD.
- SHANDONG PROVINCE MEDICINAL GLASS CO., LTD.
- SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD.
- J.O. PHARMA CO., LTD.(OTSUKA HOLDINGS CO., LTD.)
- BMI KOREA
- B. BRAUN SE
- AL SHIFA MEDICAL PRODUCTS CO.

제13장 부록

ksm

영문 목차

영문목차

The prefilled syringes market is projected to reach USD 13.1 billion by 2030 from USD 7.1 billion in 2024, at a CAGR of 10.8% during the forecast period. The prefilled syringes market has had strong growth due to a number of factors such as the rising incidences of chronic diseases like diabetes, rheumatoid arthritis, and cardiovascular disorders. Moreover, prefilled syringes make it easier to administer medications precisely and consistently to patients with chronic conditions, by providing ready-to-use doses that improve patient compliance and lower the possibility of dosage errors. Additionally, the growing trend of self-administration has also played a major role in the market's growth. Prefilled syringes are preferred by patients due to their comfort and ease of use, as they eliminate the need for dose measurement, hence improving safety and lowering the danger of contamination.

Scope of the Report
Years Considered for the Study	2022-2030
Base Year	2023
Forecast Period	2024-2030
Units Considered	Value (USD Billion)
Segments	By Type, Material, Design, Application, and Region
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries

"By type, conventional prefilled syringes segment is expected to have the largest market share in the prefilled syringes market."

Based on the type, the conventional prefilled syringes segment is expected to dominate the the prefilled syringes market due to several factors. Their ready-to-use nature and pre-measured doses enhance convenience and safety by reducing preparation time and dosing errors. They lower contamination risks and needle stick injuries through advanced safety features. Prefilled syringes improve patient compliance, particularly for chronic conditions, by being user-friendly and encouraging adherence to treatment regimens. Their versatility in therapeutic applications, especially for biologics and chronic disease treatments, coupled with the growing prevalence of such conditions, further drive their market dominance.

"By material, glass prefilled syringes segment is expected to have the largest market share in the prefilled syringes market."

Based on material, the glass prefilled syringe segment is expected to hold the largest market share in the prefilled syringes market. Their superior chemical inertness ensures drug stability and reduces the risk of interactions between the drug and the container, making them ideal for a wide range of pharmaceutical applications. Additionally, glass syringes offer high visibility, allowing for easy inspection of the drug for particulates and discoloration, which is critical for quality control and patient safety. As a result, pharmaceutical companies and healthcare providers prefer glass prefilled syringes for their reliability, safety, and efficiency in drug delivery.

"By design, single-chamber prefilled syringes segment is expected to have the largest market share in the prefilled syringes market."

Based on design, the single-chamber prefilled syringe segment accounted for the largest market share of the prefilled syringes market due to their convenience, safety, and efficiency in drug administration. These syringes, which come pre-loaded with a single dose of medication, minimize the risk of dosing errors and contamination, enhancing patient safety. They streamline the injection process, making it quicker and easier for healthcare providers and patients, thereby improving compliance and treatment outcomes. Moroever, their widespread adoption in various therapeutic areas, particularly in chronic disease management and emergency care, further drives growth in the market.

"By application, cancer segment is expected to have the largest market share in the prefilled syringes market."

By application, the cancer segment is expected to hold the largest market share due to the increasing prevalence of cancer globally and the rising need for advanced drug delivery systems. Prefilled syringes offer significant advantages for cancer treatment, including precise dosing, reduced risk of contamination, and enhanced patient safety and compliance. As cancer treatments often involve complex medication regimens requiring regular and accurate administration, the convenience and reliability of prefilled syringes become critical. Additionally, advancements in biologics and targeted therapies, which are frequently used in oncology, further drive the demand for prefilled syringes, making the cancer segment the dominant application area in this market.

"By region, North American region is expected to have the largest market share in the prefilled syringes market."

North America to register for the highest share of the prefilled syringes market during the forecast period due to several factors. These include a well-established healthcare infrastructure, high adoption rates of advanced medical technologies, and a significant focus on patient safety and convenience. Moreover, the region benefits from robust regulatory frameworks that encourage the adoption of pre-filled syringes by ensuring stringent quality standards and safety measures. Additionally, increasing incidences of chronic diseases requiring regular injections, coupled with rising healthcare expenditures, contribute to the growing demand for pre-filled syringes in North America. The presence of major pharmaceutical companies and biotechnology firms further enhances market growth through extensive research and development activities aimed at improving drug delivery systems.

A breakdown of the primary participants (supply-side) for the prefilled syringes market referred to for this report is provided below:

By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3-25%
By Designation: C-level-20%, Director Level-35%, and Others-45%
By Region: North America-27%, Europe-25%, Asia Pacific-30%, Latin America- 8%, Middle East & Africa-10% .

Prominent players in the prefilled syringes market are BD (US), Gerresheimer AG (Germany), SCHOTT (Germany), and West Pharmaceutical Services, Inc. (US), AptarGroup Inc. (US), Nipro (Japan), Baxter (US), Owen Mumford Ltd. (UK), Weigao Meidcal international Co., Ltd. (China), Credence MedSystems, Inc.(US), Novartis AG (Switzerland), Stevanato Group (Italy), Polymedicure (India), MedXL (Canada), Sharps Technology, Inc.(US), Fresenius Kabi (US), DBM S.R.L. (Italy), Taisei Kako Co.,Ltd (Japan), Shandong Province Medicinal Glass Co., Ltd.(China), SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD (Japan), J.O. PHARMA CO., LTD. (Japan), BMIKOREA (Korea), B. Braun SE ( Germany), and Al Shifa Medical Products Co. (Saudi Arabia).

Research Coverage:

The report analyzes the prefilled syringes market and aims at estimating the market size and future growth potential of this market based on various segments such as type, material, design, application, and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall prefilled syringes market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

Analysis of key drivers (increasing chronic diseases, incereasing biologics and biosimilars, and technological advancements), restraints (product recalls, and stringent government regulations), opportunities (increasing prevalence of self-administration of injectables and increasing regulatory support) and challenges (presence of alternative drug delivery methods, and infections associated with needlestick injuries)
Market Penetration: It includes extensive information on products offered by the major players in the global the prefilled syringes market. The report includes various segments in type, material, design, application, and region.
Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global prefilled syringes market.
Market Development: Thorough knowledge and analysis of the profitable rising markets by type, materila, design, application, and region.
Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global the prefilled syringes market.
Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global prefilled syringes market.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
- 1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
  - 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
  - 2.1.2.1 Key data from primary sources
  - 2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 LIMITATIONS
- 2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
2.8 IMPACT OF RECESSION ON PREFILLED SYRINGES MARKET

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PREFILLED SYRINGES MARKET OVERVIEW
4.2 ASIA PACIFIC: PREFILLED SYRINGES MARKET OVERVIEW
4.3 PREFILLED SYRINGES MARKET: REGIONAL MIX
4.4 PREFILLED SYRINGES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
4.5 PREFILLED SYRINGES MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Increasing prevalence of chronic diseases
  - 5.2.1.2 Growing adoption of self-injection devices
  - 5.2.1.3 Increasing adoption of prefilled syringes in parenteral dosage forms
  - 5.2.1.4 Increased use of biologics and vaccines
  - 5.2.1.5 Technological advancements in prefilled syringes
- 5.2.2 RESTRAINTS
  - 5.2.2.1 Stringent government regulations
  - 5.2.2.2 Impact of product recalls
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Growing preference for unit-dose medication using prefilled syringes
  - 5.2.3.2 Emerging markets with growing healthcare infrastructure
- 5.2.4 CHALLENGES
  - 5.2.4.1 Alternative drug delivery methods
  - 5.2.4.2 Infections associated with needlestick injuries
5.3 INDUSTRY TRENDS
- 5.3.1 PREFILLED BIOLOGICS
- 5.3.2 INTEGRATED SAFETY FEATURES
5.4 TECHNOLOGY ANALYSIS
- 5.4.1 KEY TECHNOLOGIES
  - 5.4.1.1 Integration disinfection unit (IDU)
- 5.4.2 COMPLEMENTARY TECHNOLOGIES
  - 5.4.2.1 Cyclic olefin polymers (COP) and cyclic olefin copolymers (COC)
- 5.4.3 ADJACENT TECHNOLOGIES
  - 5.4.3.1 Integration with autoinjectors
5.5 VALUE CHAIN ANALYSIS
5.6 PORTER'S FIVE FORCES ANALYSIS
- 5.6.1 THREAT OF NEW ENTRANTS
- 5.6.2 THREAT OF SUBSTITUTES
- 5.6.3 BARGAINING POWER OF SUPPLIERS
- 5.6.4 BARGAINING POWER OF BUYERS
- 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 REGULATORY LANDSCAPE
- 5.7.1 REGULATORY ANALYSIS
- 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 CASE STUDY ANALYSIS
- 5.8.1 CASE STUDY 1: ENVIRONMENTAL BENEFITS OF USING PREFILLED 'EMERGENCY' DRUGS
- 5.8.2 CASE STUDY 2: DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION
5.9 PRICING ANALYSIS
- 5.9.1 AVERAGE SELLING PRICE OF PREFILLED SYRINGES, BY TYPE, 2022-2024
- 5.9.2 AVERAGE SELLING PRICE TREND, BY REGION, 2022-2024
5.10 UNMET NEEDS
5.11 ECOSYSTEM ANALYSIS
5.12 SUPPLY CHAIN ANALYSIS
5.13 ADJACENT MARKET ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.15 TRADE ANALYSIS
5.16 PATENT ANALYSIS
- 5.16.1 PATENT PUBLICATION TRENDS FOR PREFILLED SYRINGES
- 5.16.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 5.16.3 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR PREFILLED SYRINGE PATENTS (JANUARY 2014-APRIL 2024)
- 5.16.4 TOP APPLICANT COUNTRIES/REGIONS PATENTS FOR PREFILLED SYRINGES (JANUARY 2014-APRIL 2024)
5.17 KEY CONFERENCES & EVENTS DURING 2024-2025
5.18 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.18.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.18.2 BUYING CRITERIA
5.19 INVESTMENT & FUNDING SCENARIO
5.20 REIMBURSEMENT SCENARIO
5.21 MARKET ANALYSIS OF PREFILLED SYRINGE COMPONENTS
- 5.21.1 PLUNGER STOPPERS

6 PREFILLED SYRINGES MARKET, BY TYPE

6.1 INTRODUCTION
6.2 CONVENTIONAL PREFILLED SYRINGES
- 6.2.1 DISPOSABLE PREFILLED SYRINGES
  - 6.2.1.1 Increasing focus on patient safety to drive market
- 6.2.2 REUSABLE PREFILLED SYRINGES
  - 6.2.2.1 Cost-effectiveness and technological advancements to drive market
6.3 SAFETY PREFILLED SYRINGES
- 6.3.1 INTEGRATED SAFETY FEATURES TO BOOST ADOPTION

7 PREFILLED SYRINGES MARKET, BY DESIGN

7.1 INTRODUCTION
7.2 SINGLE-CHAMBER PREFILLED SYRINGES
- 7.2.1 CONVENIENCE, SAFETY, AND EFFICIENCY OF SINGLE-CHAMBER SYRINGES TO SUPPORT MARKET GROWTH
7.3 DUAL-CHAMBER PREFILLED SYRINGES
- 7.3.1 UNIQUE ADVANTAGES AND SPECIFIC APPLICATIONS OF DUAL-CHAMBER SYRINGES TO DRIVE DEMAND
7.4 CUSTOMIZED PREFILLED SYRINGES
- 7.4.1 PATIENT-FRIENDLY FEATURES SUCH AS EASY-TO-READ DOSAGE INDICATORS AND SAFETY MECHANISMS TO BOOST ADOPTION

8 PREFILLED SYRINGES MARKET, BY MATERIAL

8.1 INTRODUCTION
8.2 GLASS PREFILLED SYRINGES
- 8.2.1 ABILITY OF GLASS PREFILLED SYRINGES TO OFFER SUPERIOR BARRIER PROPERTIES TO BOOST MARKET GROWTH
8.3 PLASTIC PREFILLED SYRINGES
- 8.3.1 IMPROVED SAFETY, COST-EFFECTIVENESS, VERSATILITY, AND CONVENIENCE OF PLASTIC SYRINGES TO SUPPORT ADOPTION

9 PREFILLED SYRINGES MARKET, BY APPLICATION

9.1 INTRODUCTION
9.2 DIABETES
- 9.2.1 INCREASING PREVALENCE OF DIABETES TO FAVOR MARKET GROWTH
9.3 RHEUMATOID ARTHRITIS
- 9.3.1 RISING DEMAND FOR EFFECTIVE AND CONVENIENT TREATMENT OPTIONS FOR RHEUMATOID ARTHRITIS TO DRIVE MARKET
9.4 ANAPHYLAXIS
- 9.4.1 CONVENIENCE OF PREFILLED SYRINGES TO ADMINISTER MEDICATION QUICKLY DURING ANAPHYLACTIC EPISODES TO BOOST GROWTH
9.5 CANCER
- 9.5.1 RISING GLOBAL CANCER RATES TO SUPPORT MARKET GROWTH
9.6 THROMBOSIS
- 9.6.1 MINIMIZED RISK OF CONTAMINATION AND INFECTION ASSOCIATED WITH PREFILLED SYRINGES TO DRIVE DEMAND
9.7 OPHTHALMOLOGY
- 9.7.1 FEWER SIDE-EFFECTS ASSOCIATED WITH PREFILLED SYRINGES COMPARED TO TOPICAL MEDICATIONS TO SUPPORT GROWTH
9.8 OTHER APPLICATIONS

10 PREFILLED SYRINGES MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
- 10.2.1 NORTH AMERICA: RECESSION IMPACT
- 10.2.2 US
  - 10.2.2.1 US to dominate North American prefilled syringes market
- 10.2.3 CANADA
  - 10.2.3.1 Increasing government support and rising incidence of chronic diseases to drive market
10.3 EUROPE
- 10.3.1 EUROPE: RECESSION IMPACT
- 10.3.2 GERMANY
  - 10.3.2.1 Germany to dominate market in Europe
- 10.3.3 UK
  - 10.3.3.1 Growing number of CVD and diabetes patients to drive market growth
- 10.3.4 FRANCE
  - 10.3.4.1 Increasing needlestick injuries and growing trend of self-administration to drive market growth
- 10.3.5 SPAIN
  - 10.3.5.1 Increase in biologics production to support market growth
- 10.3.6 ITALY
  - 10.3.6.1 Growing focus of pharmaceutical and medical device companies to boost market growth
- 10.3.7 REST OF EUROPE (ROE)
10.4 ASIA PACIFIC
- 10.4.1 ASIA PACIFIC: RECESSION IMPACT
- 10.4.2 JAPAN
  - 10.4.2.1 Increased geriatric population and favorable government initiatives to drive market growth in Japan
- 10.4.3 CHINA
  - 10.4.3.1 Rising prevalence of chronic diseases to augment market growth
- 10.4.4 INDIA
  - 10.4.4.1 High incidence of cancer and increased adoption of biosimilars to fuel market growth
- 10.4.5 AUSTRALIA
  - 10.4.5.1 Growing healthcare expenditure to aid market growth
- 10.4.6 SOUTH KOREA
  - 10.4.6.1 Well-developed healthcare sector and presence of major pharmaceutical manufacturers to drive market
- 10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
- 10.5.1 LATIN AMERICA: RECESSION IMPACT
- 10.5.2 BRAZIL
  - 10.5.2.1 Rising incidence of chronic diseases and increasing obesity to augment market growth
- 10.5.3 MEXICO
  - 10.5.3.1 Increasing focus of government on healthcare and growing medical tourism to propel market
- 10.5.4 ARGENTINA
  - 10.5.4.1 Increasing focus of government on healthcare and growing medical tourism to propel market
- 10.5.5 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
- 10.6.1 GROWING PUBLIC HEALTHCARE SPENDING TO BOOST MARKET
- 10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
10.7 GCC COUNTRIES
- 10.7.1 INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET
- 10.7.2 GCC COUNTRIES: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PREFILLED SYRINGES MARKET
11.3 REVENUE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 11.5.1 STARS
- 11.5.2 EMERGING LEADERS
- 11.5.3 PERVASIVE PLAYERS
- 11.5.4 PARTICIPANTS
- 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
  - 11.5.5.1 Company footprint
  - 11.5.5.2 Type footprint
  - 11.5.5.3 Material footprint
  - 11.5.5.4 Design footprint
  - 11.5.5.5 Application footprint
  - 11.5.5.6 Region footprint
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
- 11.6.1 PROGRESSIVE COMPANIES
- 11.6.2 RESPONSIVE COMPANIES
- 11.6.3 DYNAMIC COMPANIES
- 11.6.4 STARTING BLOCKS
- 11.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
11.7 BRAND/PRODUCT COMPARISON
- 11.7.1 BD
- 11.7.2 GERRESHEIMER AG
- 11.7.3 STEVANATO GROUP
- 11.7.4 SCHOTT GROUP
- 11.7.5 NIPRO
11.8 R&D EXPENDITURE
11.9 COMPETITIVE SITUATION
- 11.9.1 PRODUCT LAUNCHES
- 11.9.2 DEALS
- 11.9.3 EXPANSIONS
11.10 COMPANY VALUATION & FINANCIAL METRICS

12 COMPANY PROFILES

12.1 KEY PLAYERS
- 12.1.1 BD
  - 12.1.1.1 Business overview
  - 12.1.1.2 Products offered
  - 12.1.1.3 Recent developments
    - 12.1.1.3.1 Product launches & approvals
    - 12.1.1.3.2 Deals
    - 12.1.1.3.3 Expansions
  - 12.1.1.4 MnM view
    - 12.1.1.4.1 Right to win
    - 12.1.1.4.2 Strategic choices
    - 12.1.1.4.3 Weaknesses & competitive threats
- 12.1.2 GERRESHEIMER AG
  - 12.1.2.1 Business overview
  - 12.1.2.2 Products offered
  - 12.1.2.3 Recent developments
    - 12.1.2.3.1 Deals
    - 12.1.2.3.2 Expansions
  - 12.1.2.4 MnM view
    - 12.1.2.4.1 Right to win
    - 12.1.2.4.2 Strategic choices
    - 12.1.2.4.3 Weaknesses & competitive threats
- 12.1.3 SCHOTT
  - 12.1.3.1 Business overview
  - 12.1.3.2 Products offered
  - 12.1.3.3 Recent developments
    - 12.1.3.3.1 Expansions
  - 12.1.3.4 MnM view
    - 12.1.3.4.1 Right to win
    - 12.1.3.4.2 Strategic choices
    - 12.1.3.4.3 Weaknesses & competitive threats
- 12.1.4 WEST PHARMACEUTICAL SERVICES, INC.
  - 12.1.4.1 Business overview
  - 12.1.4.2 Products offered
  - 12.1.4.3 Recent developments
    - 12.1.4.3.1 Deals
    - 12.1.4.3.2 Expansions
- 12.1.5 APTARGROUP, INC.
  - 12.1.5.1 Business overview
  - 12.1.5.2 Products offered
  - 12.1.5.3 Recent developments
    - 12.1.5.3.1 Deals
    - 12.1.5.3.2 Expansions
- 12.1.6 NIPRO
  - 12.1.6.1 Business overview
  - 12.1.6.2 Products offered
- 12.1.7 BAXTER (SIMTRA)
  - 12.1.7.1 Business overview
  - 12.1.7.2 Products offered
  - 12.1.7.3 Recent developments
    - 12.1.7.3.1 Deals
    - 12.1.7.3.2 Expansions
- 12.1.8 OWEN MUMFORD LTD.
  - 12.1.8.1 Business overview
  - 12.1.8.2 Products offered
  - 12.1.8.3 Recent developments
    - 12.1.8.3.1 Product launches
    - 12.1.8.3.2 Deals
- 12.1.9 WEIGAO MEDICAL INTERNATIONAL CO., LTD
  - 12.1.9.1 Business overview
  - 12.1.9.2 Products offered
- 12.1.10 CREDENCE MEDSYSTEMS, INC.
  - 12.1.10.1 Business overview
  - 12.1.10.2 Products offered
- 12.1.11 NOVARTIS AG
  - 12.1.11.1 Business overview
  - 12.1.11.2 Products offered
  - 12.1.11.3 Recent developments
    - 12.1.11.3.1 Deals
- 12.1.12 STEVANATO GROUP
  - 12.1.12.1 Business overview
  - 12.1.12.2 Products offered
  - 12.1.12.3 Recent developments
    - 12.1.12.3.1 Product launches
    - 12.1.12.3.2 Deals
    - 12.1.12.3.3 Expansions
- 12.1.13 POLYMEDICURE
  - 12.1.13.1 Business overview
  - 12.1.13.2 Products offered
- 12.1.14 MEDXL INC.
  - 12.1.14.1 Business overview
  - 12.1.14.2 Products offered
- 12.1.15 SHARPS TECHNOLOGY, INC.
  - 12.1.15.1 Business overview
  - 12.1.15.2 Products offered
12.2 OTHER PLAYERS
- 12.2.1 FRESENIUS KABI USA
- 12.2.2 MEDEFIL, INC.
- 12.2.3 D.B.M. S.R.L.
- 12.2.4 TAISEI KAKO CO., LTD.
- 12.2.5 SHANDONG PROVINCE MEDICINAL GLASS CO., LTD.
- 12.2.6 SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD.
- 12.2.7 J.O. PHARMA CO., LTD. (OTSUKA HOLDINGS CO., LTD.)
- 12.2.8 BMI KOREA
- 12.2.9 B. BRAUN SE
- 12.2.10 AL SHIFA MEDICAL PRODUCTS CO.

13 APPENDIX

13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS